From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Carbonicanhydrase inhibitor 1 (compound 7c) is a carbonicanhydraseII inhibitor. Carbonicanhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
Carbonicanhydrase inhibitor 3 (compound 11g) is a carbonicanhydraseII inhibitor. Carbonicanhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
Carbonicanhydrase inhibitor 8 (compound R-13), a benzyl-derivative, is a potent human carbonicanhydrase (hCA) inhibitor with Ki values of 60.7 nM, 320.7 nM, 2298 nM for hCA I, hCA II, hCA IV, respectively .
hCAII-IN-6 (Compound S-13) is a potent human carbonicanhydraseII (hCA II) inhibitor with a Ki of 4.4 nM. hCAII-IN-6 also inhibits other hCAs isoforms I, IV and IX, with Ki values of 9.2 nM, 480.2 nM and 14.7 nM, respectively. hCAII-IN-6 can be used for glaucoma research .
Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydraseII inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
Brinzolamide (AL-4862) is a selective carbonicanhydraseII inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonicanhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .
hCAIX/XII-IN-6 is an orally active carbonicanhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .
Carbonicanhydrase inhibitor 11 (compound VI) is a potent, selective carbonicanhydrase inhibitor. Carbonicanhydrase inhibitor 11 shows Ki values of 40, 39, 200 and 900 nM against CA II, IX, and XII, respectively .
Carbonicanhydrase inhibitor 9 is a potent carbonicanhydrase (CA) inhibitor with Kis of 56.4 and 56.9 nM for hCA II and IX, respectively. Antiproliferative activity .
Carbonicanhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonicanhydrasehCA I and hCA II (Ki: 28.5 nM, 2.2 nM) .
CAII-IN-1 (compound 3n), a thiosemicarbazide derivative, is a potent, selective carbonicanhydrase-II(CA-II) inhibitor with an IC50 value of 10.3 µM for bovine CA-II. CAII-IN-1 can be used in research of carbonicanhydrase related biological disorders .
CAII-IN-2 (compound 3g), a thiosemicarbazide derivative, is a potent, selective carbonicanhydrase-II(CA-II) inhibitor with an IC50 value of 12.1 µM for bovine CA-II. CAII-IN-2 can be used in research of carbonicanhydrase related biological disorders .
Carbonicanhydrase/AChE-IN-1 (compound 16) is a carbonicanhydrase and AChE inhibitor with Kis of 24.42 nM, 19.95 nM, and 5.07 nM for hCA I, hCA II, and AChE, respectively .
Carbonicanhydrase inhibitor 14 (Compound 8b) is a carbonicanhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonicanhydrase inhibitor 14 shows antitumor activity .
Carbonicanhydrase inhibitor 18 (Compound 9) is a human carbonicanhydrase (hCA) isoform inhibitor, with Kis of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydrase inhibitor 18 can be used for the research of cancer .
Carbonicanhydrase inhibitor 5 is a potent and selective human carbonicanhydrase (hCA) inhibitor with IC50s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively .
Carbonicanhydrase inhibitor 12 is a potent CA II inhibitor, also has inhibitory activity in CA I (Kis of 1.72 and 271 nM in CA II and CA I, respectively). Carbonicanhydrase inhibitor 12 has potent anticancer activity against different cancer cell lines .
ALP/Carbonicanhydrase-IN-1 (Compound 1e) is a dual carbonicanhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonicanhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
Methazolamide (L584601) is a sulfonamide derivative used as a carbonicanhydrase inhibitor with a Ki of 14 nM for human carbonicanhydraseII. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
Carbonicanhydrase inhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonicanhydrase inhibitor 19 reveals an intraocular pressure (IOP) lowering effect .
Enpp/Carbonicanhydrase-IN-1 (compound 1e) is a potent Enpp and carbonicanhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonicanhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-1 induces Apoptosis .
Carbonicanhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonicanhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
Carbonicanhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonicanhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonicanhydrase inhibitor with a Ki of 14 nM for human carbonicanhydraseII. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].
hCAI/II-IN-1 (Compound 3h) is a human carbonicanhydrase I and II (hCA I/II) inhibitor with IC50 values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively .
hCAI/II-IN-7 (compound 1F) is a potent carbonicanhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively .
Dorzolamide (L671152) hydrochloride is a potent carbonicanhydraseII inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Dorzolamide (L671152) is a potent carbonicanhydraseII inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonicanhydrase (CA) inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV .
Halazone is an atypical antimicrobial sulfonamide derivative and a carbonicanhydraseII inhibitor with a Kd value of 1.45 µM. Halazone protects sodium channels from inactivation. Halazone is widely used for disinfection of drinking water .
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonicanhydraseII inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
hCAII-IN-7 (Compound R-13) is a potent human carbonicanhydrase(hCA) inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively .
Dorzolamide (hydrochloride) (Standard) is the analytical standard of Dorzolamide (hydrochloride). This product is intended for research and analytical applications. Dorzolamide (L671152) hydrochloride is a potent carbonicanhydraseII inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
hCAII-IN-1 (compound 7f) is a potent and selective inhibitor of carbonicanhydrase (CA II/IX) with Kis of 1.2 and 113.6 nM, respectively. hCAII-IN-1 has the potential for the research of cancer diseases .
hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonicanhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases .
hCAIX/XII-IN-9 (compound 8) is a potent carbonicanhydrase (CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .
hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonicanhydrase (hCA) inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonicanhydrase (hCA) inhibitor with Ki values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .
hCA I-IN-1 (Compound 6q) is a human carbonicanhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
hCA I-IN-2 (Compound 6d) is a selective human carbonicanhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
hCAI/II-IN-6 is an orally active human carbonicanhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
hCAXII-IN-2 (compound 5i) is a potent human carbonicanhydrase XII (hCA XII) and hCA IX inhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydraseII inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonicanhydraseII inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
hCAII-IN-9 is a potent carbonicanhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability .
Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonicanhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII) .
Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonicanhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII) .
Benzolamide (CL11366) is a potent carbonicanhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
hCAII-IN-3 (Compound 16) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity .
hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonicanhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonicanhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
hCA IX-IN-1 (Compound 6f) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonicanhydrase (CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonicanhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonicanhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
hCAIX/XII-IN-5 (Coumarin 9a) a carbonicanhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis .
hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonicanhydrase) CA IX and XII inhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II .
α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonicanhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
Zonisamide (AD 810) is an orally active carbonicanhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
Zonisamide (AD 810) sodium is an orally active carbonicanhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonicanhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonicanhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonicanhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .
Carbonic Anhydrase 2 Protein is a member of the carbonic anhydrase isozyme family, responsible for catalyzing the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. CA2 plays vital role in the regulation of ion transport and pH balance and is involved in many biological processes. Carbonic Anhydrase 2 Protein, Mouse (His) is the recombinant mouse-derived Carbonic Anhydrase 2 protein, expressed by HEK293 , with C-His labeled tag. The total length of Carbonic Anhydrase 2 Protein, Mouse (His) is 259 a.a., with molecular weight of 30-35 kDa.
Carbonic Anhydrase 2 (CA2) catalyzes the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. Two transcript variants, encoding different isoforms, have been identified. Carbonic Anhydrase 2 Protein, Human (C-His, Solution) is the recombinant human-derived Carbonic Anhydrase 2 protein, expressed by E. coli , with C-His labeled tag. The total length of Carbonic Anhydrase 2 Protein, Human (C-His, Solution) is 259 a.a., with molecular weight of ~30 kDa.
Carbonic Anhydrase 2 (CA2) catalyzes the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. Two transcript variants, encoding different isoforms, have been identified. Carbonic Anhydrase 2 Protein, Human (C-His) is the recombinant human-derived Carbonic Anhydrase 2 protein, expressed by E. coli , with C-6*His labeled tag. The total length of Carbonic Anhydrase 2 Protein, Human (C-His) is 259 a.a., with molecular weight of ~33.05 kDa.
Carbonic Anhydrase 11 Protein, Human (HEK293, His) is an approximately 38.0 kDa carbonic anhydrase 11 protein with a His-flag. Carbonic anhydrases (CAs) are found in many organisms, in which they contribute to several important biological processes.
Carbonic Anhydrase 2 (CA2) catalyzes the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. Two transcript variants, encoding different isoforms, have been identified. Carbonic Anhydrase 2 Protein, Human (HEK293, His) is the recombinant human-derived Carbonic Anhydrase 2 protein, expressed by HEK293 , with C-His labeled tag. The total length of Carbonic Anhydrase 2 Protein, Human (HEK293, His) is 260 a.a., with molecular weight of approximately 31.72 kDa.
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonicanhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonicanhydrase inhibitor with a Ki of 14 nM for human carbonicanhydraseII. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonicanhydraseII inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydraseII inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
